BVXV News and Press, BiondVax Pharmaceuticals Ltd. From 08/16/23

BiondVax Pharmaceuticals (NASDAQ: BVXV) , a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, is featured in a recent Aegis Capital Corp. research report. Aegis ti...

A new cancer treatment protocol that involves transplanting stem cells into cancer patients and then taking them through immunotherapy has proven to be quite effective at treating pediatric nerve tumors. Researchers from the Eberhard Karls University of Tübingen and St. Anna Childrenȁ...

Innovative nanobody therapeutics could deliver substantial competitive advantages in both cost and efficacy when compared to traditional monoclonal antibody therapies The biologics market was valued at $366.5 billion in 2021 and is expected to grow to a value of $719.94 billion by 2030 The mo...

2023-08-11 11:01:11 ET Biondvax Pharmaceuticals press release ( NASDAQ: BVXV ): Q2 Financial (loss) income for the three months ended June 30, 2023, amounted to $1.16 million loss compared with $0.28 million income for the three months ended June 30, 2022. Net lo...

JERUSALEM, Aug. 11, 2023 (GLOBE NEWSWIRE) -- via IBN - BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune disease...

Immunotherapy presents a relatively new means of treating cancer cells that leverages a patient’s own immune system. Rather than introduce drugs to attack and kill cancer cells, immunotherapy is more concerned with training the immune system to become more effective at finding and killing ...

Researchers from the Murdoch Children’s Research Institute (MCRI) in Australia have discovered a link between food allergy in infants and asthma with diminished lung function in later childhood years. The researchers believe their findings may help physicians be more vigilant regarding t...

BiondVax Pharmaceuticals (NASDAQ: BVXV) , a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, received an extension from NASDAQ to regain compliance with listing r...

2023-08-02 07:53:24 ET BiondVax Pharmaceuticals ( NASDAQ: BVXV ) said Nasdaq provided an extension until October end as it reviewed the biotechnology company's multi-faceted plan to regain compliance with Nasdaq’s listing rules. Previously BiondVax received a deficiency...

JERUSALEM, Aug. 01, 2023 (GLOBE NEWSWIRE) -- via IBN -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, toda...